Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

Angiotensin II Receptor BlockersIrbesartan75-300mg PO Q24HAdminister Anytime During HD; Post HD if Hypotensive

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
428<513No change900.72N/A0 (N/A)


  • Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL:
  • Inrig J. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis. 2010;23(3):290-7.
  • Marino M, Vachharajani N. Pharmacokinetics of Irbesartan Are Not Altered in Special Populations. Journal of Cardiovascular Pharmacology. 2002;40:112-122.
  • Sica D a, Marino MR, Hammett JL, et al. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clinical pharmacology and therapeutics. 1997;62(6):610-8.